The transfemoral implantation procedure is the dominant technique. It is preferred by interventional cardiologists due to its minimally invasive nature, superior safety profile, shorter hospital stays, and faster patient recovery times compared to the transapical approach.
Initially reserved for high-risk surgical patients who could not undergo open-heart surgery, TAVR eligibility has expanded significantly. Due to advanced valve technologies and clinical trial evidence, the procedure is now increasingly indicated for intermediate and even low-risk patient categories.
Key growth drivers include the global aging population, the rising prevalence of aortic stenosis, a shift in patient preference toward minimally invasive therapies, and continuous innovations in catheter design, imaging guidance, and valve durability.
While North America currently leads the market in terms of share, the Asia-Pacific region is emerging as the fastest-growing market. This is attributed to an increasing disease burden, an aging population in countries like Japan and China, and improving healthcare infrastructure.
The primary obstacles include the high cost of TAVR procedures compared to traditional surgery and the complexity of reimbursement frameworks. In many developing markets, inefficient insurance systems and a lack of universal coverage limit patient access to these advanced therapies.
The market is led by major medtech companies including Edwards Lifesciences Corporation, Medtronic plc, Boston Scientific Corporation, and Abbott Laboratories. Other significant players include Meril Life Sciences, Venus Medtech, and MicroPort Scientific Corporation.
Digital integration, particularly the use of Artificial Intelligence (AI), is transforming the market. AI-driven imaging and digital platforms are being used for pre-procedural planning, which enhances patient selection, improves surgical precision, and leads to better long-term outcomes.
In 2024, Edwards Lifesciences received European regulatory clearance for the SAPIEN 3 Ultra RESILIA system for younger, low-risk patients. Additionally, Medtronic received FDA approval for its next-generation Evolut FX system, which focuses on increased deployment precision and shorter procedure times.
Although its popularity is declining in favor of transfemoral access, the transapical approach remains a vital niche solution for patients with complex vascular anatomy or severe peripheral arterial disease where femoral access is not feasible.
